Skip to main content
Clinical Trials/NCT05963425
NCT05963425
Active, not recruiting
Not Applicable

The Effects on Physical Activity on Mitochondrial Function in Skin Fibroblasts in Patients with Parkinson's Disease: a Study Protocol.

University Ramon Llull1 site in 1 country24 target enrollmentSeptember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson's Disease
Sponsor
University Ramon Llull
Enrollment
24
Locations
1
Primary Endpoint
Change in oxygen consumption rate
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The aim of this study is to investigate the effect of physical activity on mitochondrial function in skin fibroblasts in patients with Parkinson's disease.

Detailed Description

A randomized double-blind clinical trial will be conducted to study the effects of physical activity on mitochondrial function in skin fibroblasts in patients with Parkinson's disease. It is an intervention study, and twenty-four patients will be needed. Once the subjects have been selected, they will be randomly assigned into three groups (eight patients in each group). The first group will perform basic physical training (BPT) based on strength and resistance, the second group will perform BPT combined with functional exercises (BPTFE) with cognitive and motor training, and the third group will not carry out any activity program, serving as control. The interventions will last 60 minutes, with a frequency of 3 times a week, during 16 weeks. The control group will receive 4 months of PA from the program that has obtained the best results,in terms of symptoms and quality of life, after the last evaluation.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
April 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Ramon Llull
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with a medical diagnosis of idiopathic PD, Hoehn and Yahr scale stages of I-III.
  • Patients who score ≥26 on the Montreal Cognitive Assessment (MoCA).
  • Patients who have signed the IC.
  • Patients with stable medication.
  • Age between 50 and 70 years, and able to walk independently for 6 minutes.

Exclusion Criteria

  • Patients with a pathology other than idiopathic PD.
  • Patients with cognitive impairment (MoCA \<26 points).
  • Patients with uncontrolled cardiovascular disease, visual impairment, or recent musculoskeletal disorders in the extremities.
  • Patients who are performing another therapeutic exercise protocol.
  • Patients who have undergone surgery to influence any symptom from the PD.

Outcomes

Primary Outcomes

Change in oxygen consumption rate

Time Frame: Beginning of the study and after 4 months

Oxygen uptake (VO2, mlkg-1min-1) measured by Seahorse XFe96

Change in ATPmax levels

Time Frame: Beginning of the study and after 4 months

Maximal mitochondrial ATP production rates measured by Seahorse XFe96

Secondary Outcomes

  • Non-motor and motor function(End of the study (4 Months))
  • Sleepiness(End of the study (4 Months))
  • Mobility(End of the study (4 Months))
  • Cognitive aspects(End of the study (4 Months))
  • Mood(End of the study (4 Months))

Study Sites (1)

Loading locations...

Similar Trials